Abstract<\/strong><\/header>\n
<\/header>\n
\u00c0 l\u2019instar de plusieurs pays au monde, le Mali \u00e9tait confront\u00e9 \u00e0 la pand\u00e9mie de COVID-19. Ainsi, au Mali, 30.752 personnes sont atteintes de COVID-19 entre 2020 et 2022, parmi ces patients, 29.828 patients sont gu\u00e9ris et 731 patients sont d\u00e9c\u00e9d\u00e9s (MSDS, 2022). Selon la f\u00e9d\u00e9ration internationale du diab\u00e8te (IDF Diabetes), le Mali est plus affect\u00e9 par le diab\u00e8te de type 2 avec une estimation de 1,8% (Atlas, 2021). Le diab\u00e8te et l\u2019hypertension art\u00e9rielle sont des facteurs de comorbidit\u00e9 les plus rencontr\u00e9s parmi les d\u00e9c\u00e8s de COVID-19 respectivement 20,45% et 17,42% (Kon\u00e9 B, 2021).<\/span><\/header>\n<\/div>\n
En effet, l\u2019objectif de cette \u00e9tude est d\u2019analyser les aspects clinique et biologique de la COVID-19 et du diab\u00e8te au Mali de 2020 \u00e0 2023. La pr\u00e9sente recherche constitue une \u00e9tude transversale analytique \u00e0 vis\u00e9e comparative qui porte sur les aspects clinique et biologique de la COVID-19 et du diab\u00e8te au Mali 2020 \u00e0 2023. Elle est conduite de mars 2020 \u00e0 d\u00e9cembre 2023 mais la phase de la collecte des donn\u00e9es s\u2019est d\u00e9roul\u00e9e du 2 juin au 15 d\u00e9cembre 2023 aupr\u00e8s de cinquante (50) patients retenus \u00e0 partir d\u2019un choix exhaustif issue d\u2019une analyse documentaire de 105 dossiers m\u00e9dicaux de patients au niveau de l\u2019h\u00f4pital du Mali et dans les Centre de Sant\u00e9 de R\u00e9f\u00e9rence (CSR\u00e9f) de la commune I et commune VI. Ainsi, le recueil des donn\u00e9es est effectu\u00e9 \u00e0 domicile sous forme d\u2019entretiens individuels avec les patients. Ensuite l\u2019analyse et le traitement des donn\u00e9es sont r\u00e9alis\u00e9s \u00e0 partir du logiciel SPSS version 21 et des logiciels office 2016 Excel et Word.Toutefois, l\u2019\u00e9tude a montr\u00e9 qu\u2019avant la pand\u00e9mie, 34% des patients sont ob\u00e8ses tandis qu\u2019aucun patient ob\u00e8se n\u2019est enregistr\u00e9 durant et apr\u00e8s la pandemie. Aussi, avant la pand\u00e9mie, 54% des patients ont un diab\u00e8te d\u00e9s\u00e9quilibr\u00e9. \u00a0En plus, durant la pand\u00e9mie, 18% des patients ont d\u00e9satur\u00e9 tandis qu\u2019aucun patient n\u2019a d\u00e9satur\u00e9 avant et apr\u00e8s l\u2019infection \u00e0 COVID-19. Cette d\u00e9saturation en oxyg\u00e8ne est plus remarquable chez les hommes (59%) plus que chez les femmes (41%) de la tranche d\u2019\u00e2ge de 65-74 ans. Puis, des cas d\u2019acidoc\u00e9toses diab\u00e9tiques sont enregistr\u00e9s seulement durant la pandemie chez 6% des patients. Cependant l\u2019hypertension art\u00e9rielle (HTA) est la seule complication macro angiopathique retrouv\u00e9e chez les patients avec une augmentation de sa fr\u00e9quence durant la pand\u00e9mie. Quant \u00e0 la d\u00e9tresse respiratoire, elle est observ\u00e9e chez 25% des patients lors de l\u2019infection \u00e0 COVID-19 contre cinq 29% des patients apr\u00e8s la pand\u00e9mie. Sur le plan curatif, cinquante-sept pourcent (57%) des soignants ont utilis\u00e9 l\u2019insuline pour traiter l\u2019hyperglyc\u00e9mie au cours du diab\u00e8te et 14% des soignants ont trait\u00e9 la COVID-19 selon protocole en vigueur au Mali.<\/p>\n
Enfin, les aspects clinique et biologique de la COVID-19 et du diab\u00e8te au Mali 2020 \u00e0 2023, ont prouv\u00e9 qu\u2019il y a un lien entre les complications aigue du diab\u00e8te et la pand\u00e9mie. Ce qui permet d\u2019affirmer que le diab\u00e8te est un facteur de risque associ\u00e9 au diab\u00e8te au m\u00eame titre que le diab\u00e8te pour alt\u00e9rer la sant\u00e9 des patients.<\/p>\n
\u00a0<\/strong>Mots-cl\u00e9s : <\/strong>Aspect Clinique, Biologique COVID-19, Diab\u00e8te, Bamako, Mali<\/p>\n
\n
Summary:<\/strong><\/p>\n
Like many countries around the world, Mali was faced with the COVID-19 pandemic. In Mali, 30,752 people were affected by COVID-19 between 2020 and 2022, of whom 29,828 were cured and 731 died (MSDS, 2022).<\/p>\n
According to the International Diabetes Federation (IDF Diabetes), Mali is more affected by type 2 diabetes, with an estimated 1.8% (Atlas, 2021). Diabetes and hypertension are the most common comorbidities among COVID-19 deaths, at 20.45% and 17.42% respectively (Kon\u00e9 B, 2021).<\/p>\n
The aim of this study is to analyze the clinical and biological aspects of COVID-19 and diabetes in Mali from 2020 to 2023. The present research constitutes a comparative cross-sectional analytical study of the clinical and biological aspects of COVID-19 and diabetes in Mali 2020 to 2023. It was conducted from March 2020 to December 2023, but the data collection phase took place from June 2 to December 15, 2023, with fifty (50) patients chosen from an exhaustive selection based on a documentary analysis of 105 patients’ medical records at the Hospital of Mali and in the Referral Health Centers (CSR\u00e9f) of Commune I and Commune VI. Data were collected at home, in the form of individual interviews with patients. Data analysis and processing were then carried out using SPSS version 21 software and Office 2016 Excel and Word.<\/p>\n
However, the study showed that before the pandemic, 34% of patients were obese, while no obese patients were recorded during or after the pandemic. In addition, before the pandemic, 54% of patients had unbalanced diabetes.\u00a0 In addition, during the pandemic, 18% of patients desaturated, whereas no patients desaturated before or after the COVID-19 infection. This oxygen desaturation was more remarkable in men (59%) than in women (41%) in the 65-74 age group. Cases of diabetic ketoacidosis were recorded in only 6% of patients during the pandemic. However, arterial hypertension (AH) was the only macro-angiopathic complication found in patients, with an increase in frequency during the pandemic. Respiratory distress was observed in 25% of patients during COVID-19 infection, compared with five 29% of patients after the pandemic. On the curative side, fifty-seven percent (57%) of caregivers used insulin to treat hyperglycemia during diabetes, and 14% of caregivers treated COVID-19 according to the protocol in force in Mali.<\/p>\n
Finally, the clinical and biological aspects of COVID-19 and diabetes in Mali 2020 to 2023, proved that there is a link between the acute complications of diabetes and the pandemic. This means that diabetes is just as much a risk factor associated with diabetes as diabetes is for altering patients’ health.<\/p>\n
\u00a0<\/strong>Keywords: <\/strong>Clinical, Biological Aspect COVID-19, Diabetes, Bamako, Mali<\/span><\/p>\n<\/header>\n
\n
\n
\n
Titre<\/strong> : Aspects clinique et biologique de la covid-19 Et du diab\u00e8te au Mali de 2020 \u00e0 2023
\nAuteurs<\/strong> : ISSA LENDE. M ; DRAGO AA Diakaridia KONE \u00b2 ; Togo A\u00b2 ; SOW Djeneba ; BERTHE B ; NIZEYIMAN JB ; KAMBALE NGUOMOJA I ; MESENGE C ; KONE K ; IBRAHIM MOUSSA AK ; TRAORE M<\/p>\n
Publi\u00e9 dans\u00a0<\/strong>\u00a0\u00a0Journal des sciences sociales et de l\u2019ing\u00e9nierie<\/a>\u00a0,\u00a0\u00a0 Volume 36<\/a>\u00a0\u00a0,\u00a0\u00a0<\/em>num\u00e9ro 1<\/a>
\ndoi<\/strong>\u00a0:\u00a010.55272\/rufso.rjsse<\/a>
\n<\/em><\/p>\n
T\u00e9l\u00e9charger l\u2019article en PDF<\/a><\/strong><\/h3>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
Abstract \u00c0 l\u2019instar de plusieurs pays au monde, le Mali \u00e9tait confront\u00e9 \u00e0 la pand\u00e9mie de COVID-19. Ainsi, au Mali, 30.752 personnes sont atteintes de COVID-19 entre 2020 et 2022, parmi ces patients, 29.828 patients sont gu\u00e9ris et 731 patients sont d\u00e9c\u00e9d\u00e9s (MSDS, 2022). Selon la f\u00e9d\u00e9ration internationale du diab\u00e8te (IDF Diabetes), le Mali est…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_kad_post_transparent":"default","_kad_post_title":"default","_kad_post_layout":"default","_kad_post_sidebar_id":"","_kad_post_content_style":"default","_kad_post_vertical_padding":"default","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[174,38,177,220,222],"tags":[],"class_list":["post-3341","post","type-post","status-publish","format-standard","hentry","category-article","category-health-and-biomedical-sciences","category-jsse","category-rjsse-volume-36","category-rufso-rjsse-volume-36-issue-1"],"_links":{"self":[{"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/posts\/3341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/comments?post=3341"}],"version-history":[{"count":1,"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/posts\/3341\/revisions"}],"predecessor-version":[{"id":3343,"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/posts\/3341\/revisions\/3343"}],"wp:attachment":[{"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/media?parent=3341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/categories?post=3341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rufso.ac.cd\/journal\/rjsse\/wp-json\/wp\/v2\/tags?post=3341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}